Literature DB >> 10491326

Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin.

X Zi1, R Agarwal.   

Abstract

Recently we showed that the skin cancer preventive effect of silymarin involves inhibition of erbB1 activation. Here we assessed the effect of silymarin on cytoplasmic and nuclear signals employing human epidermoid carcinoma A431 cells. Silymarin treatment of cells resulted in a significant inhibition of mitogen-activated protein kinase (MAPK)/ERK1/2 activation only at lower doses, whereas higher doses activated MAPK/JNK1. These differential responses of silymarin were accompanied by its growth inhibitory and apoptotic cell death effects at low and high doses, respectively. Silymarin-caused growth inhibition was via both G2-M and G1 arrests due to a significant decrease in the kinase activity and protein levels of CDKs and cyclins. In other studies, only low doses of silymarin also showed an induction of Cip1/p21 and Kip1/p27. Together, these results identify distinct signaling pathways for the antiproliferative and apoptotic effects of silymarin and form a basis for developing strategies targeted to ERK and JNK pathways for the prevention and intervention of malignancies by silymarin. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491326     DOI: 10.1006/bbrc.1999.1398

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Prevention of non-melanoma skin cancer.

Authors:  S P Stratton
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.

Authors:  Jing Zhang; Jonathan S Harrison; George P Studzinski
Journal:  Exp Cell Res       Date:  2010-09-08       Impact factor: 3.905

Review 3.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

4.  Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.

Authors:  Pham Quang Vinh; Shigeyuki Sugie; Takuji Tanaka; Akira Hara; Yasuhiro Yamada; Masaki Katayama; Takashi Deguchi; Hideki Mori
Journal:  Jpn J Cancer Res       Date:  2002-01

Review 5.  Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity.

Authors:  Dominique Delmas; Jianbo Xiao; Anne Vejux; Virginie Aires
Journal:  Molecules       Date:  2020-04-25       Impact factor: 4.411

Review 6.  Mechanistic Insights into the Pharmacological Significance of Silymarin.

Authors:  Karan Wadhwa; Rakesh Pahwa; Manish Kumar; Shobhit Kumar; Prabodh Chander Sharma; Govind Singh; Ravinder Verma; Vineet Mittal; Inderbir Singh; Deepak Kaushik; Philippe Jeandet
Journal:  Molecules       Date:  2022-08-21       Impact factor: 4.927

Review 7.  Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics.

Authors:  Yung-Yi Cheng; Chen-Hsi Hsieh; Tung-Hu Tsai
Journal:  J Food Drug Anal       Date:  2018-02-03       Impact factor: 6.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.